Company / Profit Margin
Inhibrx Biosciences, Inc. Profit Margin History
FY2024-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-10773.5%
FY2025
5-year range
-13408.9% / -10773.5%
FY2024-FY2025
Trend
+19.7%
vs FY2024
Sector context
#144 of 146
Health Care
What the data says
Among 146 Health Care companies, Inhibrx Biosciences, Inc. is in the bottom 1% for profit margin.
Based on SEC 10-K filings.
-10773.5% in FY2025.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 1% in Health CareTop 99% of 146This company -10773.5% Sector average -796.3%
▼
-1253.0% below sector average
Key checks
Key Insights
- In FY2025, profit margin increased 19.7% year-over-year.
- Currently 9977.2pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -10773.5% | +19.7% |
| FY2024 | -13408.9% | - |
| FY2023 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026